In 2006, Shinya Yamanaka discovered that adult somatic cells can be reprogrammed into an embryonic-like pluripotent state by delivering transcription factors. These reprogrammed cells, known as induced pluripotent stem (iPS) cells, have the potential to develop into every cell type in the body and are invaluable tools for disease modeling, drug screening, and cell therapy. iPS cells also provide an unprecedented opportunity for discovery in life science, and in Yamanaka’s lab today, researchers continue to use them to investigate the mechanisms for cell fate determination, the reprogramming process, and pluripotency.
Areas of Expertise
Work from Yamanaka’s lab has demonstrated that a few transcription factors in combinations can reprogram cell fate from somatic lineages back to a pluripotent state. This groundbreaking work established the field of iPS cell technology, and hundreds of scientists are now trying to bring the technology to patients. Continuing efforts in Yamanaka’s lab to elucidate the mechanisms underlying pluripotency and reprogramming revealed that beyond the action of transcription factors, post-transcriptional regulation is also critical for cell fate determination. For example, they demonstrated that NAT1 (eIF4G2), a translation initiation factor, plays multiple roles in human stem cells depending on differentiation status. Their research addresses complex interactions between transcriptional control and post-transcriptional regulation, and contributes to innovative therapeutic options for patients including gene and cell therapies.
Senior Investigator, Gladstone Institutes
L.K. Whittier Foundation Investigator in Stem Cell Biology
Professor of Anatomy, UC San Francisco
Director and Professor, Center for iPS Cell Research and Application (CiRA), Kyoto University (Japan)
Shinya Yamanaka, MD, PhD, is a senior investigator and the L.K. Whittier Foundation Investigator in Stem Cell Biology at Gladstone Institutes. He is also a professor of anatomy at UC San Francisco, as well as a director and professor of the Center for iPS Cell Research and Application (CiRA) at Kyoto University in Japan.
Yamanaka earned an MD from Kobe University and a PhD from Osaka City University. From 1987 to 1989, he was a resident at the National Osaka Hospital. From 1993 to 1995, he was a postdoctoral fellow at Gladstone. Yamanaka then became an assistant professor at Osaka City University Medical School, and later an associate professor at Nara Institute of Science and Technology, where he eventually became a full professor in 2003. He took his current professor position at Kyoto University in 2004, and was appointed senior investigator at Gladstone Institutes in 2007. Since 2008, he has been directing CiRA.
In 2012, Yamanaka was awarded the Nobel Prize in Physiology or Medicine for his discovery that adult somatic cells can be reprogrammed into pluripotent cells. In addition, he has received many awards and honors, including the Albert Lasker Basic Medical Research Award, the Wolf Prize in Medicine, the Millennium Technology Award, the Shaw Prize, the Kyoto Prize for Advanced Technology, the Gairdner International Award, the Robert Koch Award, and the March of Dimes Prize.
How Did You Get Your Start in Science?
“As a young doctor, I saw many patients suffering from intractable diseases, including my own father. I want to overcome those diseases with science.”
Honors and Awards
2018 The 69th NHK (Japan Broadcasting Corporation) Broadcasting Culture Award, Japan
2018 Honorary degree, the Bulgarian Academy of Sciences
2018 Honorary degree, the University of Tampere
2016 Honorary Distinguished Professor, Hiroshima University, Japan
2015 The Visionary Award by Glaucoma Research Foundation, USA
2015 Elected to the National Academy of Medicine as an International Member, USA
2015 Degree of Doctor of Science, honoris causa awarded by the Chinese University of Hong Kong
2015 Elected to Academy of Sciences, Institute de France as a Foreign Associate, France
2015 UCSF 150th Anniversary Alumni Excellence Award
2014 Honorary Degree awarded by the University of Hong Kong
2014 JANE Innovation Award, Japan
2014 Honorary degree, 56th Convocation Ceremony, The Rockefeller University
2013 Honored Citizen of Kyoto City, Japan
2013 Honored Citizen of Higashiosaka City, Japan
2013 The 2013 Kyoto University Shi-Shi Award, Japan
2013 Breakthrough Prize in Life Sciences, Milner Foundation, Isle of Man
2013 Commitment to a Cure Award, The ALS Association Golden West Chapter
2013 Special Honor Award of the Kyoto Medical Association, Japan
2013 World Visionary Award (Sponsored by Japan Society of Northern California), USA
2013 Member, the Japan Academy (Elected)
2012 Osaka Governor’s Award, Japan
2012 Order of Cultural Merit, Japan
2012 Kyoto Prefecture People’s Honor Award, Japan
2012 Millennium Technology Prize, Technology Academy Finland
2012 The Kyoto Prefecture Culture Prize, Eminent Merits Prize, Japan
2012 Bunka-Kunsho (Order of Culture), Japan
2012 Osaka Award for Challenge and Pioneer Spirit, Osaka Chamber of Commerce and Industry, Japan
2012 The 47th Osaka City Award, Japan
2012 Nobel Prize in Physiology or Medicine
2011 Warren Triennial Prize, Massachusetts General Hospital
2011 King Faisal International Prize for Science (Medicine), Saudi Arabia
2011 11th Annual Albany Medical Center Prize in Medicine and Biomedical Research
2011 Wolf Prize in Medicine, Israel
2011 Foreign Associate, National Academy of Sciences (Elected)
2011 Distinguished Leadership Award, Japan Society of Boston
2011 ISSCR McEwen Centre Award for Innovation
2010 26th annual Kyoto Prize in Advanced Technology, Japan
2010 Balzan Prize for Stem Cells, Italy
2010 BBVA Foundation Frontiers of Knowledge Award in the Biomedicine category, Spain
2010 March of Dimes Prize in Developmental Biology
2010 Mayor of Osaka Special Award, Japan
2010 100th Imperial Prize and Japan Academy Prize, The Japan Academy, Japan
2010 Kyoto Medal of Honor, Japan
2010 Person of Cultural Merit, Japan
2010 Medical Award, Japan Medical Association, Japan
2010 Honorary Professor by the Nara Institute of Science and Technology (NAIST)
2010 Honorary Doctor of Science Degree, Mount Sinai School of Medicine, USA
2009 Nikkei BP Technology Award, Nikkei Business Publications, Inc., Japan
2009 Lewis S. Rosenstiel Award for Distinguished Work in Basic Medical Science
2009 Canada Gairdner International Award, The Gairdner Foundation, Canada
2009 Albert Lasker Basic Medical Research Award, Lasker Foundation
2009 Honorary doctorate by the Kumamoto University
2008 Special Prize, Kyoto Souzousya Taisho Awards, Japan
2008 Takeda Prize for Medical Science, Japan
2008 Medals of Honor from the Japanese Government (“Shiju Hosho”, Medals with Purple Ribbon), Japan
2008 Massry Prize, Meira and Shaul G. Massry Foundation
2008 Kyoto Newspaper Taisho, Japan
2008 Lifetime Scientific Achievement Award, American Skin Association
2008 Asahi Award, Asahi Newspaper Co., Japan
2008 Inoue Prize for Science, Japan
2008 Golden Plate Award and Guest of Honor, International Achievement Summit, Academy of Achievement
2008 Robert-Koch Preis, Germany
2008 Nikkei BP Golden Award, Nikkei Business Publications, Inc., Japan
2008 The Special Prize for Science and Technology, the Minister of Education, Culture, Sports, Science and Technology, Japan
2008 Chunichi Cultural Prize, Chunichi Newspaper Co., Japan
2008 The Shaw Prize in Life Science and Medicine, Hong Kong
2008 One of the “TIME 100”, TIME magazine’s most influential people in the world
2008 The Sixth Takamine Memorial Sankyo Prize, Japan
2007 JSPS Prize, Japan Society for the Promotion of Science
2007 Twenty-Fifth Osaka Science Prize, Japan
2007 Meyenburg Cancer Research Award, Germany
2007 Nikkei BP Technology Award, Nikkei Business Publications, Inc., Japan
2004 Gold Medal, Tokyo Techno Forum 21, Japan
2004 Nice-Step researcher, National Institute of Science and Technology Policy (NISTEP), Japan
2003 NAIST Award, Nara Institute of Science and Technology, Japan
- Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges. Yamanaka S. Cell Stem Cell. 2020 Oct 01; 27(4):523-531.
- Critical Roles of Translation Initiation and RNA Uridylation in Endogenous Retroviral Expression and Neural Differentiation in Pluripotent Stem Cells. Takahashi K, Jeong D, Wang S, Narita M, Jin X, Iwasaki M, Perli SD, Conklin BR, Yamanaka S. Cell Rep. 2020 06 02; 31(9):107715.
- Base-Resolution Methylome of Retinal Pigment Epithelial Cells Used in the First Trial of Human Induced Pluripotent Stem Cell-Based Autologous Transplantation. Araki H, Miura F, Watanabe A, Morinaga C, Kitaoka F, Kitano Y, Sakai N, Shibata Y, Terada M, Goto S, Yamanaka S, Takahashi M, Ito T. Stem Cell Reports. 2019 10 08; 13(4):761-774.
- Induced 2C Expression and Implantation-Competent Blastocyst-like Cysts from Primed Pluripotent Stem Cells. Kime C, Kiyonari H, Ohtsuka S, Kohbayashi E, Asahi M, Yamanaka S, Takahashi M, Tomoda K. Stem Cell Reports. 2019 09 10; 13(3):485-498.
- Generation of a human induced pluripotent stem cell line, BRCi001-A, derived from a patient with mucopolysaccharidosis type I. Suga M, Kondo T, Imamura K, Shibukawa R, Okanishi Y, Sagara Y, Tsukita K, Enami T, Furujo M, Saijo K, Nakamura Y, Osawa M, Saito MK, Yamanaka S, Inoue H. Stem Cell Res. 2019 04; 36:101406.
- Application of induced pluripotent stem cells to primary immunodeficiency diseases. Karagiannis P, Yamanaka S, Saito MK. Exp Hematol. 2019 03; 71:43-50.
- Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development. Karagiannis P, Takahashi K, Saito M, Yoshida Y, Okita K, Watanabe A, Inoue H, Yamashita JK, Todani M, Nakagawa M, Osawa M, Yashiro Y, Yamanaka S, Osafune K. Physiol Rev. 2019 01 01; 99(1):79-114.
- Concise Review: Laying the Groundwork for a First-In-Human Study of an Induced Pluripotent Stem Cell-Based Intervention for Spinal Cord Injury. Tsuji O, Sugai K, Yamaguchi R, Tashiro S, Nagoshi N, Kohyama J, Iida T, Ohkubo T, Itakura G, Isoda M, Shinozaki M, Fujiyoshi K, Kanemura Y, Yamanaka S, Nakamura M, Okano H. Stem Cells. 2019 01; 37(1):6-13.
- MYC Releases Early Reprogrammed Human Cells from Proliferation Pause via Retinoblastoma Protein Inhibition. Rand TA, Sutou K, Tanabe K, Jeong D, Nomura M, Kitaoka F, Tomoda E, Narita M, Nakamura M, Nakamura M, Watanabe A, Rulifson E, Yamanaka S, Takahashi K. Cell Rep. 2018 Apr 10; 23(2):361-375.
- Structural and spatial chromatin features at developmental gene loci in human pluripotent stem cells. Ikeda H, Sone M, Yamanaka S, Yamamoto T. Nat Commun. 2017 11 20; 8(1):1616.
- Epigenetic foundations of pluripotent stem cells that recapitulate in vivo pluripotency. Yagi M, Yamanaka S, Yamada Y. Lab Invest. 2017 10; 97(10):1133-1141.
- MHC matching improves engraftment of iPSC-derived neurons in non-human primates. Morizane A, Kikuchi T, Hayashi T, Mizuma H, Takara S, Doi H, Mawatari A, Glasser MF, Shiina T, Ishigaki H, Itoh Y, Okita K, Yamasaki E, Doi D, Onoe H, Ogasawara K, Yamanaka S, Takahashi J. Nat Commun. 2017 08 30; 8(1):385.
- Enhanced Therapeutic Effects of Human iPS Cell Derived-Cardiomyocyte by Combined Cell-Sheets with Omental Flap Technique in Porcine Ischemic Cardiomyopathy Model. Kawamura M, Miyagawa S, Fukushima S, Saito A, Miki K, Funakoshi S, Yoshida Y, Yamanaka S, Shimizu T, Okano T, Daimon T, Toda K, Sawa Y. Sci Rep. 2017 08 18; 7(1):8824.
- Induced Pluripotent Stem Cells 10 Years Later: For Cardiac Applications. Yoshida Y, Yamanaka S. Circ Res. 2017 Jun 09; 120(12):1958-1968.
- The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Imamura K, Izumi Y, Watanabe A, Tsukita K, Woltjen K, Yamamoto T, Hotta A, Kondo T, Kitaoka S, Ohta A, Tanaka A, Watanabe D, Morita M, Takuma H, Tamaoka A, Kunath T, Wray S, Furuya H, Era T, Makioka K, Okamoto K, Fujisawa T, Nishitoh H, Homma K, Ichijo H, Julien JP, Obata N, Hosokawa M, Akiyama H, Kaneko S, Ayaki T, Ito H, Kaji R, Takahashi R, Yamanaka S, Inoue H. Sci Transl Med. 2017 05 24; 9(391).
- Hybrid Cellular Metabolism Coordinated by Zic3 and Esrrb Synergistically Enhances Induction of Naive Pluripotency. Sone M, Morone N, Nakamura T, Tanaka A, Okita K, Woltjen K, Nakagawa M, Heuser JE, Yamada Y, Yamanaka S, Yamamoto T. Cell Metab. 2017 May 02; 25(5):1103-1117.e6.
- New Models for Therapeutic Innovation from Japan. Karagiannis P, Onodera A, Yamanaka S. EBioMedicine. 2017 04; 18:3-4.
- Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration. Mandai M, Watanabe A, Kurimoto Y, Hirami Y, Morinaga C, Daimon T, Fujihara M, Akimaru H, Sakai N, Shibata Y, Terada M, Nomiya Y, Tanishima S, Nakamura M, Kamao H, Sugita S, Onishi A, Ito T, Fujita K, Kawamata S, Go MJ, Shinohara C, Hata KI, Sawada M, Yamamoto M, Ohta S, Ohara Y, Yoshida K, Kuwahara J, Kitano Y, Amano N, Umekage M, Kitaoka F, Tanaka A, Okada C, Takasu N, Ogawa S, Yamanaka S, Takahashi M. N Engl J Med. 2017 03 16; 376(11):1038-1046.
- Nat1 promotes translation of specific proteins that induce differentiation of mouse embryonic stem cells. Sugiyama H, Takahashi K, Yamamoto T, Iwasaki M, Narita M, Nakamura M, Rand TA, Nakagawa M, Watanabe A, Yamanaka S. Proc Natl Acad Sci U S A. 2017 01 10; 114(2):340-345.
- Induced pluripotent stem cell technology: a decade of progress. Shi Y, Inoue H, Wu JC, Yamanaka S. Nat Rev Drug Discov. 2017 02; 16(2):115-130.
- BMP-SMAD-ID promotes reprogramming to pluripotency by inhibiting p16/INK4A-dependent senescence. Hayashi Y, Hsiao EC, Sami S, Lancero M, Schlieve CR, Nguyen T, Yano K, Nagahashi A, Ikeya M, Matsumoto Y, Nishimura K, Fukuda A, Hisatake K, Tomoda K, Asaka I, Toguchida J, Conklin BR, Yamanaka S. Proc Natl Acad Sci U S A. 2016 11 15; 113(46):13057-13062.
- Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia. Sasaki K, Makiyama T, Yoshida Y, Wuriyanghai Y, Kamakura T, Nishiuchi S, Hayano M, Harita T, Yamamoto Y, Kohjitani H, Hirose S, Chen J, Kawamura M, Ohno S, Itoh H, Takeuchi A, Matsuoka S, Miura M, Sumitomo N, Horie M, Yamanaka S, Kimura T. PLoS One. 2016; 11(10):e0164795.
- Autotaxin-mediated lipid signaling intersects with LIF and BMP signaling to promote the naive pluripotency transcription factor program. Kime C, Sakaki-Yumoto M, Goodrich L, Hayashi Y, Sami S, Derynck R, Asahi M, Panning B, Yamanaka S, Tomoda K. Proc Natl Acad Sci U S A. 2016 11 01; 113(44):12478-12483.
- MicroRNA-302 switch to identify and eliminate undifferentiated human pluripotent stem cells. Parr CJ, Katayama S, Miki K, Kuang Y, Yoshida Y, Morizane A, Takahashi J, Yamanaka S, Saito H. Sci Rep. 2016 09 09; 6:32532.
- Epigenetic Variation between Human Induced Pluripotent Stem Cell Lines Is an Indicator of Differentiation Capacity. Nishizawa M, Chonabayashi K, Nomura M, Tanaka A, Nakamura M, Inagaki A, Nishikawa M, Takei I, Oishi A, Tanabe K, Ohnuki M, Yokota H, Koyanagi-Aoi M, Okita K, Watanabe A, Takaori-Kondo A, Yamanaka S, Yoshida Y. Cell Stem Cell. 2016 09 01; 19(3):341-54.
- Identification of MMP1 as a novel risk factor for intracranial aneurysms in ADPKD using iPSC models. Ameku T, Taura D, Sone M, Numata T, Nakamura M, Shiota F, Toyoda T, Matsui S, Araoka T, Yasuno T, Mae S, Kobayashi H, Kondo N, Kitaoka F, Amano N, Arai S, Ichisaka T, Matsuura N, Inoue S, Yamamoto T, Takahashi K, Asaka I, Yamada Y, Ubara Y, Muso E, Fukatsu A, Watanabe A, Sato Y, Nakahata T, Mori Y, Koizumi A, Nakao K, Yamanaka S, Osafune K. Sci Rep. 2016 07 15; 6:30013.
- Screening of Human cDNA Library Reveals Two differentiation-Related Genes, HHEX and HLX, as Promoters of Early Phase Reprogramming toward Pluripotency. Yamakawa T, Sato Y, Matsumura Y, Kobayashi Y, Kawamura Y, Goshima N, Yamanaka S, Okita K. Stem Cells. 2016 11; 34(11):2661-2669.
- Establishment of Human Neural Progenitor Cells from Human Induced Pluripotent Stem Cells with Diverse Tissue Origins. Fukusumi H, Shofuda T, Bamba Y, Yamamoto A, Kanematsu D, Handa Y, Okita K, Nakamura M, Yamanaka S, Okano H, Kanemura Y. Stem Cells Int. 2016; 2016:7235757.
- When Myc's asleep, embryonic stem cells are dormant. Nakagawa M, Karagiannis P, Yamanaka S. EMBO J. 2016 Apr 15; 35(8):801-2.
- SOX2 O-GlcNAcylation alters its protein-protein interactions and genomic occupancy to modulate gene expression in pluripotent cells. Myers SA, Peddada S, Chatterjee N, Friedrich T, Tomoda K, Krings G, Thomas S, Maynard J, Broeker M, Thomson M, Pollard K, Yamanaka S, Burlingame AL, Panning B. Elife. 2016 Mar 07; 5:e10647.
- Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies. Azuma K, Yamanaka S. Regen Ther. 2016 Jun; 4:36-47.
- A decade of transcription factor-mediated reprogramming to pluripotency. Takahashi K, Yamanaka S. Nat Rev Mol Cell Biol. 2016 Mar; 17(3):183-93.
- Enhanced engraftment, proliferation, and therapeutic potential in heart using optimized human iPSC-derived cardiomyocytes. Funakoshi S, Miki K, Takaki T, Okubo C, Hatani T, Chonabayashi K, Nishikawa M, Takei I, Oishi A, Narita M, Hoshijima M, Kimura T, Yamanaka S, Yoshida Y. Sci Rep. 2016 Jan 08; 6:19111.
- Efficient CRISPR/Cas9-Based Genome Engineering in Human Pluripotent Stem Cells. Kime C, Mandegar MA, Srivastava D, Yamanaka S, Conklin BR, Rand TA. Curr Protoc Hum Genet. 2016 Jan 01; 88:21.4.1-21.4.23.
- Inducible Transgene Expression in Human iPS Cells Using Versatile All-in-One piggyBac Transposons. Kim SI, Oceguera-Yanez F, Sakurai C, Nakagawa M, Yamanaka S, Woltjen K. Methods Mol Biol. 2016; 1357:111-31.
- A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of allogeneic human induced pluripotent stem(-Like) cells. Hayakawa T, Aoi T, Umezawa A, Ozawa K, Sato Y, Sawa Y, Matsuyama A, Yamanaka S, Yamato M. Regen Ther. 2015 Dec; 2:95-108.
- A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of autologous human somatic stem cells. Hayakawa T, Aoi T, Umezawa A, Ozawa K, Sato Y, Sawa Y, Matsuyama A, Yamanaka S, Yamato M. Regen Ther. 2015 Dec; 2:57-69.
- A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of autologous human induced pluripotent stem(-like) cells. Hayakawa T, Aoi T, Umezawa A, Ozawa K, Sato Y, Sawa Y, Matsuyama A, Yamanaka S, Yamato M. Regen Ther. 2015 Dec; 2:81-94.
- Practical Integration-Free Episomal Methods for Generating Human Induced Pluripotent Stem Cells. Kime C, Rand TA, Ivey KN, Srivastava D, Yamanaka S, Tomoda K. Curr Protoc Hum Genet. 2015 Oct 06; 87:21.2.1-21.2.21.
- A developmental framework for induced pluripotency. Takahashi K, Yamanaka S. Development. 2015 Oct 01; 142(19):3274-85.
- From Genomics to Gene Therapy: Induced Pluripotent Stem Cells Meet Genome Editing. Hotta A, Yamanaka S. Annu Rev Genet. 2015; 49:47-70.
- Cell Therapy Using Human Induced Pluripotent Stem Cell-Derived Renal Progenitors Ameliorates Acute Kidney Injury in Mice. Toyohara T, Mae S, Sueta S, Inoue T, Yamagishi Y, Kawamoto T, Kasahara T, Hoshina A, Toyoda T, Tanaka H, Araoka T, Sato-Otsubo A, Takahashi K, Sato Y, Yamaji N, Ogawa S, Yamanaka S, Osafune K. Stem Cells Transl Med. 2015 Sep; 4(9):980-92.
- Robust In Vitro Induction of Human Germ Cell Fate from Pluripotent Stem Cells. Sasaki K, Yokobayashi S, Nakamura T, Okamoto I, Yabuta Y, Kurimoto K, Ohta H, Moritoki Y, Iwatani C, Tsuchiya H, Nakamura S, Sekiguchi K, Sakuma T, Yamamoto T, Mori T, Woltjen K, Nakagawa M, Yamamoto T, Takahashi K, Yamanaka S, Saitou M. Cell Stem Cell. 2015 Aug 06; 17(2):178-94.
- Efficient Detection and Purification of Cell Populations Using Synthetic MicroRNA Switches. Miki K, Endo K, Takahashi S, Funakoshi S, Takei I, Katayama S, Toyoda T, Kotaka M, Takaki T, Umeda M, Okubo C, Nishikawa M, Oishi A, Narita M, Miyashita I, Asano K, Hayashi K, Osafune K, Yamanaka S, Saito H, Yoshida Y. Cell Stem Cell. 2015 Jun 04; 16(6):699-711.
- Direct cardiac reprogramming: progress and challenges in basic biology and clinical applications. Sadahiro T, Yamanaka S, Ieda M. Circ Res. 2015 Apr 10; 116(8):1378-91.
- Structure-based discovery of NANOG variant with enhanced properties to promote self-renewal and reprogramming of pluripotent stem cells. Hayashi Y, Caboni L, Das D, Yumoto F, Clayton T, Deller MC, Nguyen P, Farr CL, Chiu HJ, Miller MD, Elsliger MA, Deacon AM, Godzik A, Lesley SA, Tomoda K, Conklin BR, Wilson IA, Yamanaka S, Fletterick RJ. Proc Natl Acad Sci U S A. 2015 Apr 14; 112(15):4666-71.
- KLF4 N-terminal variance modulates induced reprogramming to pluripotency. Kim SI, Oceguera-Yanez F, Hirohata R, Linker S, Okita K, Yamada Y, Yamamoto T, Yamanaka S, Woltjen K. Stem Cell Reports. 2015 Apr 14; 4(4):727-43.
- Development of a global network of induced pluripotent stem cell haplobanks. Wilmut I, Leslie S, Martin NG, Peschanski M, Rao M, Trounson A, Turner D, Turner ML, Yamanaka S, Taylor CJ. Regen Med. 2015; 10(3):235-8.
- The homeobox gene DLX4 promotes generation of human induced pluripotent stem cells. Sci Rep. 2014 Dec 04; 4:7283.
- Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports. 2015 Jan 13; 4(1):143-154.
- Computational image analysis of colony and nuclear morphology to evaluate human induced pluripotent stem cells. Tokunaga K, Saitoh N, Goldberg IG, Sakamoto C, Yasuda Y, Yoshida Y, Yamanaka S, Nakao M. Sci Rep. 2014 Nov 11; 4:6996.
- The fate of cell reprogramming. Nat Methods. 2014 Oct; 11(10):1006-8.
- Dynamic regulation of human endogenous retroviruses mediates factor-induced reprogramming and differentiation potential. Proc Natl Acad Sci U S A. 2014 Aug 26; 111(34):12426-31.
- Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells. Nat Biotechnol. 2014 Aug; 32(8):724-6.
- Calcium transients closely reflect prolonged action potentials in iPSC models of inherited cardiac arrhythmia. Spencer CI, Baba S, Nakamura K, Hua EA, Sears MA, Fu CC, Zhang J, Balijepalli S, Tomoda K, Hayashi Y, Lizarraga P, Wojciak J, Scheinman MM, Aalto-Setälä K, Makielski JC, January CT, Healy KE, Kamp TJ, Yamanaka S, Conklin BR. Stem Cell Reports. 2014 Aug 12; 3(2):269-81.
- Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice. Stem Cell Reports. 2014 Aug 12; 3(2):242-9.
- Induction of pluripotency in human somatic cells via a transient state resembling primitive streak-like mesendoderm. Nat Commun. 2014 Apr 24; 5:3678.
- Involvement of ER stress in dysmyelination of Pelizaeus-Merzbacher Disease with PLP1 missense mutations shown by iPSC-derived oligodendrocytes. Stem Cell Reports. 2014 May 06; 2(5):648-61.
- Generation and characterization of induced pluripotent stem cells from Aid-deficient mice. Shimamoto R, Amano N, Ichisaka T, Watanabe A, Yamanaka S, Okita K. PLoS One. 2014; 9(4):e94735.
- A chemical probe that labels human pluripotent stem cells. Cell Rep. 2014 Mar 27; 6(6):1165-1174.
- Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells. Cell Stem Cell. 2014 Apr 03; 14(4):535-48.
- Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. Cell. 2014 Feb 13; 156(4):663-77.
- iPS cells: a game changer for future medicine. EMBO J. 2014 Mar 03; 33(5):409-17.
- Perspectives for induced pluripotent stem cell technology: new insights into human physiology involved in somatic mosaicism. Circ Res. 2014 Jan 31; 114(3):505-10.
- Efficient and rapid induction of human iPSCs/ESCs into nephrogenic intermediate mesoderm using small molecule-based differentiation methods. PLoS One. 2014; 9(1):e84881.
- Cell-autonomous correction of ring chromosomes in human induced pluripotent stem cells. Nature. 2014 Mar 06; 507(7490):99-103.
- A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells. Sci Rep. 2014 Jan 08; 4:3594.
- Induction of pluripotency by defined factors. Proc Jpn Acad Ser B Phys Biol Sci. 2014; 90(3):83-96.
- Induced pluripotent stem cells from patients with human fibrodysplasia ossificans progressiva show increased mineralization and cartilage formation. Orphanet J Rare Dis. 2013 Dec 09; 8:190.
- Tsix RNA and the germline factor, PRDM14, link X reactivation and stem cell reprogramming. Mol Cell. 2013 Dec 26; 52(6):805-18.
- Differentiation-defective phenotypes revealed by large-scale analyses of human pluripotent stem cells. Proc Natl Acad Sci U S A. 2013 Dec 17; 110(51):20569-74.
- The winding road to pluripotency (Nobel Lecture). Angew Chem Int Ed Engl. 2013 Dec 23; 52(52):13900-9.
- The let-7/LIN-41 pathway regulates reprogramming to human induced pluripotent stem cells by controlling expression of prodifferentiation genes. Cell Stem Cell. 2014 Jan 02; 14(1):40-52.
- Global splicing pattern reversion during somatic cell reprogramming. Cell Rep. 2013 Oct 31; 5(2):357-66.
- Toward the development of a global induced pluripotent stem cell library. Cell Stem Cell. 2013 Oct 03; 13(4):382-4.
- Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. Stem Cell Reports. 2013; 1(4):283-92.
- Tudor domain containing 12 (TDRD12) is essential for secondary PIWI interacting RNA biogenesis in mice. Proc Natl Acad Sci U S A. 2013 Oct 08; 110(41):16492-7.
- Maturation, not initiation, is the major roadblock during reprogramming toward pluripotency from human fibroblasts. Proc Natl Acad Sci U S A. 2013 Jul 23; 110(30):12172-9.
- Making steady progress on direct cardiac reprogramming toward clinical application. Circ Res. 2013 Jun 21; 113(1):13-5.
- Response to comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells". Sci Transl Med. 2013 Jun 05; 5(188):188lr2.
- Induced pluripotent stem cells in medicine and biology. Development. 2013 Jun; 140(12):2457-61.
- To be immunogenic, or not to be: that's the iPSC question. Cell Stem Cell. 2013 Apr 04; 12(4):385-6.
- An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells. 2013 Mar; 31(3):458-66.
- Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aß and differential drug responsiveness. Cell Stem Cell. 2013 Apr 04; 12(4):487-96.
- Ultrastructural maturation of human-induced pluripotent stem cell-derived cardiomyocytes in a long-term culture. Circ J. 2013; 77(5):1307-14.
- Steps toward safe cell therapy using induced pluripotent stem cells. Circ Res. 2013 Feb 01; 112(3):523-33.
- Human induced pluripotent stem cell-derived ectodermal precursor cells contribute to hair follicle morphogenesis in vivo. J Invest Dermatol. 2013 Jun; 133(6):1479-88.
- Epigenetic regulation in pluripotent stem cells: a key to breaking the epigenetic barrier. Philos Trans R Soc Lond B Biol Sci. 2013 Jan 05; 368(1609):20120292.
- Cartilage tissue engineering identifies abnormal human induced pluripotent stem cells. Sci Rep. 2013; 3:1978.
- Monitoring and robust induction of nephrogenic intermediate mesoderm from human pluripotent stem cells. Nat Commun. 2013; 4:1367.
- Shinya Yamanaka: purveyor of pluripotency. Interview by Ruth Williams. Circ Res. 2013 Jan 18; 112(2):233-5.
- Rapid and deep profiling of human induced pluripotent stem cell proteome by one-shot NanoLC-MS/MS analysis with meter-scale monolithic silica columns. J Proteome Res. 2013 Jan 04; 12(1):214-21.
- Generation of naive-like porcine-induced pluripotent stem cells capable of contributing to embryonic and fetal development. Stem Cells Dev. 2013 Feb 01; 22(3):473-82.
- Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med. 2012 Aug 01; 4(145):145ra104.
- Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells. Proc Natl Acad Sci U S A. 2012 Jul 31; 109(31):12538-43.
- Derivation conditions impact X-inactivation status in female human induced pluripotent stem cells. Cell Stem Cell. 2012 Jul 06; 11(1):91-9.
- Induced pluripotent stem cells from CINCA syndrome patients as a model for dissecting somatic mosaicism and drug discovery. Blood. 2012 Aug 09; 120(6):1299-308.
- Induced pluripotent stem cells: past, present, and future. Cell Stem Cell. 2012 Jun 14; 10(6):678-684.
- Stem cells assessed. Nat Rev Mol Cell Biol. 2012 06 08; 13(7):471-6.
- Germline development from human pluripotent stem cells toward disease modeling of infertility. Fertil Steril. 2012 Jun; 97(6):1250-9.
- Bioengineered myocardium derived from induced pluripotent stem cells improves cardiac function and attenuates cardiac remodeling following chronic myocardial infarction in rats. Stem Cells Transl Med. 2012 May; 1(5):430-7.
- [Research for cell therapy by induced pluripotent stem cell]. Nihon Rinsho. 2011 Dec; 69(12):2114-8.
- Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol. 2011 Nov 27; 29(12):1132-44.
- Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech. 2012 Mar; 5(2):220-30.
- Glis1, a unique pro-reprogramming factor, may facilitate clinical applications of iPSC technology. . 2011 Nov 01; 10(21):3613-4.
- Integration-free iPS cells engineered using human artificial chromosome vectors. PLoS One. 2011; 6(10):e25961.
- Anti-Aß drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease. PLoS One. 2011; 6(9):e25788.
- Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice. Proc Natl Acad Sci U S A. 2011 Oct 04; 108(40):16825-30.
- Immunogenicity of induced pluripotent stem cells. Okita K, Nagata N, Yamanaka S. Circ Res. 2011 Sep 16; 109(7):720-1.
- Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum Mol Genet. 2011 Dec 01; 20(23):4530-9.
- Essential roles of ECAT15-2/Dppa2 in functional lung development. Mol Cell Biol. 2011 Nov; 31(21):4366-78.
- Specific lectin biomarkers for isolation of human pluripotent stem cells identified through array-based glycomic analysis. Cell Res. 2011 Nov; 21(11):1551-63.
- Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression. Uosaki H, Fukushima H, Takeuchi A, Matsuoka S, Nakatsuji N, Yamanaka S, Yamashita JK. PLoS One. 2011; 6(8):e23657.
- Induced pluripotent stem cells: opportunities and challenges. Philos Trans R Soc Lond B Biol Sci. 2011 Aug 12; 366(1575):2198-207.
- Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1. Nature. 2011 Jun 08; 474(7350):225-9.
- The nomenclature system should be sustainable, but also practical. Cell Stem Cell. 2011 Jun 03; 8(6):606-7.
- ECAT11/L1td1 is enriched in ESCs and rapidly activated during iPSC generation, but it is dispensable for the maintenance and induction of pluripotency. PLoS One. 2011; 6(5):e20461.
- A more efficient method to generate integration-free human iPS cells. Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S, Hong H, Nakagawa M, Tanabe K, Tezuka K, Shibata T, Kunisada T, Takahashi M, Takahashi J, Saji H, Yamanaka S. Nat Methods. 2011 May; 8(5):409-12.
- Induction and enhancement of cardiac cell differentiation from mouse and human induced pluripotent stem cells with cyclosporin-A. Fujiwara M, Yan P, Otsuji TG, Narazaki G, Uosaki H, Fukushima H, Kuwahara K, Harada M, Matsuda H, Matsuoka S, Okita K, Takahashi K, Nakagawa M, Ikeda T, Sakata R, Mummery CL, Nakatsuji N, Yamanaka S, Nakao K, Yamashita JK. PLoS One. 2011 Feb 22; 6(2):e16734.
- Genome-sequencing anniversary. Of mice and humans. Yamanaka S. Science. 2011 Feb 18; 331(6019):873.
- Generation of human melanocytes from induced pluripotent stem cells. Ohta S, Imaizumi Y, Okada Y, Akamatsu W, Kuwahara R, Ohyama M, Amagai M, Matsuzaki Y, Yamanaka S, Okano H, Kawakami Y. PLoS One. 2011 Jan 13; 6(1):e16182.
- Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells. Takayama N, Nishimura S, Nakamura S, Shimizu T, Ohnishi R, Endo H, Yamaguchi T, Otsu M, Nishimura K, Nakanishi M, Sawaguchi A, Nagai R, Takahashi K, Yamanaka S, Nakauchi H, Eto K. J Exp Med. 2010 Dec 20; 207(13):2817-30.
- [Derivation of engraftable myogenic precursors from murine ES/iPS cells and generation of disease-specific iPS cells from patients with Duchenne muscular dystrophy (DMD) and other diseases]. Rinsho Shinkeigaku. 2010 Nov; 50(11):889.
- iPS cells: a source of cardiac regeneration. Yoshida Y, Yamanaka S. J Mol Cell Cardiol. 2011 Feb; 50(2):327-32.
- Gingival fibroblasts as a promising source of induced pluripotent stem cells. Egusa H, Okita K, Kayashima H, Yu G, Fukuyasu S, Saeki M, Matsumoto T, Yamanaka S, Yatani H. PLoS One. 2010 Sep 14; 5(9):e12743.
- Induction of primordial germ cells from mouse induced pluripotent stem cells derived from adult hepatocytes. Imamura M, Aoi T, Tokumasu A, Mise N, Abe K, Yamanaka S, Noce T. Mol Reprod Dev. 2010 Sep; 77(9):802-11.
- Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice. Espejel S, Roll GR, McLaughlin KJ, Lee AY, Zhang JY, Laird DJ, Okita K, Yamanaka S, Willenbring H. J Clin Invest. 2010 Sep; 120(9):3120-6.
- Promotion of direct reprogramming by transformation-deficient Myc. Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S. Proc Natl Acad Sci U S A. 2010 Aug 10; 107(32):14152-7.
- Recent stem cell advances: induced pluripotent stem cells for disease modeling and stem cell-based regeneration. Yoshida Y, Yamanaka S. Circulation. 2010 Jul 06; 122(1):80-7.
- Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury. Tsuji O, Miura K, Okada Y, Fujiyoshi K, Mukaino M, Nagoshi N, Kitamura K, Kumagai G, Nishino M, Tomisato S, Higashi H, Nagai T, Katoh H, Kohda K, Matsuzaki Y, Yuzaki M, Ikeda E, Toyama Y, Nakamura M, Yamanaka S, Okano H. Proc Natl Acad Sci U S A. 2010 Jul 13; 107(28):12704-9.
- Patient-specific pluripotent stem cells become even more accessible. Yamanaka S. Cell Stem Cell. 2010 Jul 02; 7(1):1-2.
- miRNAs regulate SIRT1 expression during mouse embryonic stem cell differentiation and in adult mouse tissues. Saunders LR, Sharma AD, Tawney J, Nakagawa M, Okita K, Yamanaka S, Willenbring H, Verdin E. Aging (Albany NY). 2010 Jul; 2(7):415-31.
- Cell line-dependent differentiation of induced pluripotent stem cells into cardiomyocytes in mice. Kaichi S, Hasegawa K, Takaya T, Yokoo N, Mima T, Kawamura T, Morimoto T, Ono K, Baba S, Doi H, Yamanaka S, Nakahata T, Heike T. Cardiovasc Res. 2010 Nov 01; 88(2):314-23.
- Nuclear reprogramming to a pluripotent state by three approaches. Yamanaka S, Blau HM. Nature. 2010 Jun 10; 465(7299):704-12.
- Genome-wide DNA methylation profile of tissue-dependent and differentially methylated regions (T-DMRs) residing in mouse pluripotent stem cells. Sato S, Yagi S, Arai Y, Hirabayashi K, Hattori N, Iwatani M, Okita K, Ohgane J, Tanaka S, Wakayama T, Yamanaka S, Shiota K. Genes Cells. 2010 Jun; 15(6):607-18.
- An interview with... Shinya Yamanaka. Interview by Mary Muers. Yamanaka S. Nat Rev Genet. 2010 Jun; 11(6):390.
- Induction of pluripotency by defined factors. Okita K, Yamanaka S. Exp Cell Res. 2010 Oct 01; 316(16):2565-70.
- Sirt1 plays an important role in mediating greater functionality of human ES/iPS-derived vascular endothelial cells. Homma K, Sone M, Taura D, Yamahara K, Suzuki Y, Takahashi K, Sonoyama T, Inuzuka M, Fukunaga Y, Tamura N, Itoh H, Yamanaka S, Nakao K. Atherosclerosis. 2010 Sep; 212(1):42-7.
- Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells. Mizuno Y, Chang H, Umeda K, Niwa A, Iwasa T, Awaya T, Fukada S, Yamamoto H, Yamanaka S, Nakahata T, Heike T. FASEB J. 2010 Jul; 24(7):2245-53.
- Generation of mouse-induced pluripotent stem cells with plasmid vectors. Okita K, Hong H, Takahashi K, Yamanaka S. Nat Protoc. 2010 Mar; 5(3):418-28.
- Reprogramming of somatic cells to pluripotency. Adv Exp Med Biol. 2010; 695:215-24.
- Complete genetic correction of ips cells from Duchenne muscular dystrophy. Kazuki Y, Hiratsuka M, Takiguchi M, Osaki M, Kajitani N, Hoshiya H, Hiramatsu K, Yoshino T, Kazuki K, Ishihara C, Takehara S, Higaki K, Nakagawa M, Takahashi K, Yamanaka S, Oshimura M. Mol Ther. 2010 Feb; 18(2):386-93.
- Human induced pluripotent stem cells on autologous feeders. Takahashi K, Narita M, Yokura M, Ichisaka T, Yamanaka S. PLoS One. 2009 Dec 02; 4(12):e8067.
- Efficient reprogramming of human and mouse primary extra-embryonic cells to pluripotent stem cells. Nagata S, Toyoda M, Yamaguchi S, Hirano K, Makino H, Nishino K, Miyagawa Y, Okita H, Kiyokawa N, Nakagawa M, Yamanaka S, Akutsu H, Umezawa A, Tada T. Genes Cells. 2009 Dec; 14(12):1395-404.
- G(i)-coupled GPCR signaling controls the formation and organization of human pluripotent colonies. Nakamura K, Salomonis N, Tomoda K, Yamanaka S, Conklin BR. PLoS One. 2009 Nov 10; 4(11):e7780.
- Orderly hematopoietic development of induced pluripotent stem cells via Flk-1(+) hemoangiogenic progenitors. Niwa A, Umeda K, Chang H, Saito M, Okita K, Takahashi K, Nakagawa M, Yamanaka S, Nakahata T, Heike T. J Cell Physiol. 2009 Nov; 221(2):367-77.
- Induced pluripotent stem cells and reprogramming: seeing the science through the hype. Izpisúa Belmonte JC, Ellis J, Hochedlinger K, Yamanaka S. Nat Rev Genet. 2009 12; 10(12):878-83.
- Ekiden to iPS Cells. Yamanaka S. Nat Med. 2009 Oct; 15(10):1145-8.
- Transplantation of mouse induced pluripotent stem cells into the cochlea. Nishimura K, Nakagawa T, Ono K, Ogita H, Sakamoto T, Yamamoto N, Okita K, Yamanaka S, Ito J. Neuroreport. 2009 Sep 23; 20(14):1250-4.
- Hypoxia enhances the generation of induced pluripotent stem cells. Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S. Cell Stem Cell. 2009 Sep 04; 5(3):237-41.
- Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S. Nature. 2009 Aug 27; 460(7259):1132-5.
- The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Yokoo N, Baba S, Kaichi S, Niwa A, Mima T, Doi H, Yamanaka S, Nakahata T, Heike T. Biochem Biophys Res Commun. 2009 Sep 25; 387(3):482-8.
- Variation in the safety of induced pluripotent stem cell lines. Miura K, Okada Y, Aoi T, Okada A, Takahashi K, Okita K, Nakagawa M, Koyanagi M, Tanabe K, Ohnuki M, Ogawa D, Ikeda E, Okano H, Yamanaka S. Nat Biotechnol. 2009 Aug; 27(8):743-5.
- Elite and stochastic models for induced pluripotent stem cell generation. Yamanaka S. Nature. 2009 Jul 02; 460(7251):49-52.
- Generation and characterization of human induced pluripotent stem cells. Ohnuki M, Takahashi K, Yamanaka S. Curr Protoc Stem Cell Biol. 2009 Jun; Chapter 4:Unit 4A.2.
- In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. Tanaka T, Tohyama S, Murata M, Nomura F, Kaneko T, Chen H, Hattori F, Egashira T, Seki T, Ohno Y, Koshimizu U, Yuasa S, Ogawa S, Yamanaka S, Yasuda K, Fukuda K. Biochem Biophys Res Commun. 2009 Aug 07; 385(4):497-502.
- Roles of Sall4 in the generation of pluripotent stem cells from blastocysts and fibroblasts. Tsubooka N, Ichisaka T, Okita K, Takahashi K, Nakagawa M, Yamanaka S. Genes Cells. 2009 Jun; 14(6):683-94.
- Induction and isolation of vascular cells from human induced pluripotent stem cells--brief report. Taura D, Sone M, Homma K, Oyamada N, Takahashi K, Tamura N, Yamanaka S, Nakao K. Arterioscler Thromb Vasc Biol. 2009 Jul; 29(7):1100-3.
- Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells. Senju S, Haruta M, Matsunaga Y, Fukushima S, Ikeda T, Takahashi K, Okita K, Yamanaka S, Nishimura Y. Stem Cells. 2009 May; 27(5):1021-31.
- Generation of retinal cells from mouse and human induced pluripotent stem cells. Hirami Y, Osakada F, Takahashi K, Okita K, Yamanaka S, Ikeda H, Yoshimura N, Takahashi M. Neurosci Lett. 2009 Jul 24; 458(3):126-31.
- A fresh look at iPS cells. Yamanaka S. Cell. 2009 Apr 03; 137(1):13-7.
- Broader implications of defining standards for the pluripotency of iPSCs. Daley GQ, Lensch MW, Jaenisch R, Meissner A, Plath K, Yamanaka S. Cell Stem Cell. 2009 Mar 06; 4(3):200-1; author reply 202.
- Adipogenic differentiation of human induced pluripotent stem cells: comparison with that of human embryonic stem cells. Taura D, Noguchi M, Sone M, Hosoda K, Mori E, Okada Y, Takahashi K, Homma K, Oyamada N, Inuzuka M, Sonoyama T, Ebihara K, Tamura N, Itoh H, Suemori H, Nakatsuji N, Okano H, Yamanaka S, Nakao K. FEBS Lett. 2009 Mar 18; 583(6):1029-33.
- ERas is expressed in primate embryonic stem cells but not related to tumorigenesis. Tanaka Y, Ikeda T, Kishi Y, Masuda S, Shibata H, Takeuchi K, Komura M, Iwanaka T, Muramatsu S, Kondo Y, Takahashi K, Yamanaka S, Hanazono Y. Cell Transplant. 2009; 18(4):381-9.
- Defining developmental potency and cell lineage trajectories by expression profiling of differentiating mouse embryonic stem cells. Aiba K, Nedorezov T, Piao Y, Nishiyama A, Matoba R, Sharova LV, Sharov AA, Yamanaka S, Niwa H, Ko MS. DNA Res. 2009 Feb; 16(1):73-80.
- Generation of mouse induced pluripotent stem cells without viral vectors. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Science. 2008 Nov 07; 322(5903):949-53.
- Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Narazaki G, Uosaki H, Teranishi M, Okita K, Kim B, Matsuoka S, Yamanaka S, Yamashita JK. Circulation. 2008 Jul 29; 118(5):498-506.
- Pluripotency and nuclear reprogramming. Yamanaka S. Philos Trans R Soc Lond B Biol Sci. 2008 Jun 27; 363(1500):2079-87.
- Generation of pluripotent stem cells from adult mouse liver and stomach cells. Aoi T, Yae K, Nakagawa M, Ichisaka T, Okita K, Takahashi K, Chiba T, Yamanaka S. Science. 2008 Aug 01; 321(5889):699-702.
- Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, Mochiduki Y, Takizawa N, Yamanaka S. Nat Biotechnol. 2008 Jan; 26(1):101-6.
- Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Cell. 2007 Nov 30; 131(5):861-72.
- New advances in iPS cell research do not obviate the need for human embryonic stem cells. Hyun I, Hochedlinger K, Jaenisch R, Yamanaka S. Cell Stem Cell. 2007 Oct 11; 1(4):367-8.
- Reprogramming somatic cells towards pluripotency by defined factors. Lewitzky M, Yamanaka S. Curr Opin Biotechnol. 2007 Oct; 18(5):467-73.
- Drosophila NAT1, a homolog of the vertebrate translational regulator NAT1/DAP5/p97, is required for embryonic germband extension and metamorphosis. Yoshikane N, Nakamura N, Ueda R, Ueno N, Yamanaka S, Nakamura M. Dev Growth Differ. 2007 Sep; 49(7):623-34.
- Strategies and new developments in the generation of patient-specific pluripotent stem cells. Yamanaka S. Cell Stem Cell. 2007 Jun 07; 1(1):39-49.
- Generation of germline-competent induced pluripotent stem cells. Okita K, Ichisaka T, Yamanaka S. Nature. 2007 Jul 19; 448(7151):313-7.
- Induction of pluripotent stem cells from fibroblast cultures. Takahashi K, Okita K, Nakagawa M, Yamanaka S. Nat Protoc. 2007; 2(12):3081-9.
- [Induction of pluripotent stem cells from mouse fibroblast cultures]. Yamanaka S, Takahashi K. Tanpakushitsu Kakusan Koso. 2006 Dec; 51(15):2346-51.
- Dnmt3a2 targets endogenous Dnmt3L to ES cell chromatin and induces regional DNA methylation. Nimura K, Ishida C, Koriyama H, Hata K, Yamanaka S, Li E, Ura K, Kaneda Y. Genes Cells. 2006 Oct; 11(10):1225-37.
- Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Takahashi K, Yamanaka S. Cell. 2006 Aug 25; 126(4):663-76.
- Esg1, expressed exclusively in preimplantation embryos, germline, and embryonic stem cells, is a putative RNA-binding protein with broad RNA targets. Tanaka TS, Lopez de Silanes I, Sharova LV, Akutsu H, Yoshikawa T, Amano H, Yamanaka S, Gorospe M, Ko MS. Dev Growth Differ. 2006 Aug; 48(6):381-90.
- Transcriptional repression and DNA hypermethylation of a small set of ES cell marker genes in male germline stem cells. Imamura M, Miura K, Iwabuchi K, Ichisaka T, Nakagawa M, Lee J, Kanatsu-Shinohara M, Shinohara T, Yamanaka S. BMC Dev Biol. 2006 Jul 21; 6:34.
- Identification and targeted disruption of the mouse gene encoding ESG1 (PH34/ECAT2/DPPA5). Amano H, Itakura K, Maruyama M, Ichisaka T, Nakagawa M, Yamanaka S. BMC Dev Biol. 2006 Feb 28; 6:11.
- Identification of genes involved in tumor-like properties of embryonic stem cells. Takahashi K, Ichisaka T, Yamanaka S. Methods Mol Biol. 2006; 329:449-58.
- Intracellular signaling pathways regulating pluripotency of embryonic stem cells. Okita K, Yamanaka S. Curr Stem Cell Res Ther. 2006 Jan; 1(1):103-11.
- Utilization of digital differential display to identify novel targets of Oct3/4. Tokuzawa Y, Maruyama M, Yamanaka S. Methods Mol Biol. 2006; 329:223-31.
- [Molecular mechanisms underlying pluripotency of embryonic stem cells]. Yamanaka S. Seikagaku. 2006 Jan; 78(1):27-33.
- Differential membrane localization of ERas and Rheb, two Ras-related proteins involved in the phosphatidylinositol 3-kinase/mTOR pathway. Takahashi K, Nakagawa M, Young SG, Yamanaka S. J Biol Chem. 2005 Sep 23; 280(38):32768-74.
- Complete and durable remission of refractory mantle cell lymphoma with repeated rituximab monotherapy. Ishiyama K, Takami A, Okumura H, Ozaki J, Shimadoi S, Yamanaka S, Nakao S. Int J Hematol. 2005 May; 81(4):319-22.
- [Mechanism for maintaining pluripotency in embryonic stem cells and inner cell mass]. Nakagawa M, Yamanaka S. Tanpakushitsu Kakusan Koso. 2005 May; 50(6 Suppl):546-50.
- Differential roles for Sox15 and Sox2 in transcriptional control in mouse embryonic stem cells. Maruyama M, Ichisaka T, Nakagawa M, Yamanaka S. J Biol Chem. 2005 Jul 01; 280(26):24371-9.
- Evolutionarily conserved non-AUG translation initiation in NAT1/p97/DAP5 (EIF4G2). Takahashi K, Maruyama M, Tokuzawa Y, Murakami M, Oda Y, Yoshikane N, Makabe KW, Ichisaka T, Yamanaka S. Genomics. 2005 Mar; 85(3):360-71.
- Multiple functions of Jab1 are required for early embryonic development and growth potential in mice. Tomoda K, Yoneda-Kato N, Fukumoto A, Yamanaka S, Kato JY. J Biol Chem. 2004 Oct 08; 279(41):43013-8.
- Expression profiling with arrays of randomly disrupted genes in mouse embryonic stem cells leads to in vivo functional analysis. Matsuda E, Shigeoka T, Iida R, Yamanaka S, Kawaichi M, Ishida Y. Proc Natl Acad Sci U S A. 2004 Mar 23; 101(12):4170-4.
- The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M, Yamanaka S. Cell. 2003 May 30; 113(5):631-42.
- Role of ERas in promoting tumour-like properties in mouse embryonic stem cells. Takahashi K, Mitsui K, Yamanaka S. Nature. 2003 May 29; 423(6939):541-5.
- Fbx15 is a novel target of Oct3/4 but is dispensable for embryonic stem cell self-renewal and mouse development. Tokuzawa Y, Kaiho E, Maruyama M, Takahashi K, Mitsui K, Maeda M, Niwa H, Yamanaka S. Mol Cell Biol. 2003 Apr; 23(8):2699-708.
- Low expression of the apolipoprotein B mRNA-editing transgene in mice reduces LDL levels but does not cause liver dysplasia or tumors. Qian X, Balestra ME, Yamanaka S, Borén J, Lee I, Innerarity TL. Arterioscler Thromb Vasc Biol. 1998 Jun; 18(6):1013-20.
- A novel translational repressor mRNA is edited extensively in livers containing tumors caused by the transgene expression of the apoB mRNA-editing enzyme. Yamanaka S, Poksay KS, Arnold KS, Innerarity TL. Genes Dev. 1997 Feb 01; 11(3):321-33.
- Hyperediting of multiple cytidines of apolipoprotein B mRNA by APOBEC-1 requires auxiliary protein(s) but not a mooring sequence motif. Yamanaka S, Poksay KS, Driscoll DM, Innerarity TL. J Biol Chem. 1996 May 10; 271(19):11506-10.
- Cloning and mutagenesis of the rabbit ApoB mRNA editing protein. A zinc motif is essential for catalytic activity, and noncatalytic auxiliary factor(s) of the editing complex are widely distributed. Yamanaka S, Poksay KS, Balestra ME, Zeng GQ, Innerarity TL. J Biol Chem. 1994 Aug 26; 269(34):21725-34.